CRC Research Update — June 06, 2026
Today's colorectal cancer research highlights
msi-h
A collection of 14 issues
CRC Research Update — June 04, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 01, 2026
Today's colorectal cancer research highlights
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
Dual immunotherapy shows durable benefit in MSI-H colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy shows durable benefit in MSI-H colorectal cancer — Journal of Clinical Oncology
Long-term follow-up from the CheckMate 8HW phase 3 trial examined outcomes in patients with MSI-H/dMMR (microsatellite instability-high/mismatch repair-deficient) metastatic colorectal cancer treated with nivolumab plus ipilimumab versus
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
Skip to content
The CRC Digest
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
In a study of Lynch syndrome carriers, 83% of advanced adenomas and 58% of adenomas were mismatch repair-deficient, and the presence of Nous-209 mutations correlated strongly with microsatellite instability status, suggesting potential for preventive immunotherapy.
CRC Research Update — April 19, 2026
Today's colorectal cancer research highlights